Integra LifeSciences (NASDAQ:IART) Hits New 12-Month High – Still a Buy?

Integra LifeSciences Holdings Corporation (NASDAQ:IART) reached a new 52-week high during trading on Monday . The stock traded as high as $20.32 and last traded at $20.27, with a volume of 88953 shares trading hands. The stock had previously closed at $19.79.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on IART shares. BMO Capital Markets started coverage on shares of Integra LifeSciences in a research note on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price target for the company. Citigroup reissued a “neutral” rating and issued a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Wall Street Zen downgraded shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. Finally, Wells Fargo & Company lifted their price target on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $18.43.

Integra LifeSciences Trading Up 1.2%

The company has a market cap of $1.54 billion, a P/E ratio of -3.06, a PEG ratio of 1.35 and a beta of 1.22. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75. The business has a 50 day moving average price of $17.61 and a 200-day moving average price of $13.41.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.13. The business had revenue of $391.92 million during the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The firm’s revenue was up 2.4% on a year-over-year basis. During the same period last year, the business earned $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of IART. SG Americas Securities LLC bought a new stake in Integra LifeSciences in the 4th quarter valued at $4,722,000. Hsbc Holdings PLC acquired a new stake in Integra LifeSciences during the 4th quarter valued at $879,000. Tejara Capital Ltd boosted its position in Integra LifeSciences by 42.6% during the fourth quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock worth $2,134,000 after purchasing an additional 51,300 shares during the period. Systematic Financial Management LP boosted its position in Integra LifeSciences by 4.5% during the fourth quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock worth $13,769,000 after purchasing an additional 48,094 shares during the period. Finally, UBS Group AG increased its holdings in shares of Integra LifeSciences by 211.7% in the fourth quarter. UBS Group AG now owns 408,969 shares of the life sciences company’s stock valued at $5,079,000 after purchasing an additional 277,745 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.